|XDATA – June 12th 2017|
|Intralytix disclosed raising $17.5 million as part of a non-brokered equity private placement. One investor acquired the securities almost two weeks ago. The equity offering’s estimated net proceeds amount to $15.62 million excluding $1.88 million earmarked for the payment of officers’ salaries. No offering was previously initiated by the company under a registration exemption with the SEC.|
|The company is a biotechnology specialized in bacteriophage-based products used to control bacterial pathogens in environmental, food processing, and medical settings.|
|The company is headquartered in Baltimore MD. Intralytix elected to keep its revenues undisclosed.
The executive team includes Alexander Sulakvelidze, John J Woloszyn and Mel Ruzicka.
The board of directors includes Gary Pasterneck and Patrick Hervy.
Amount offered: $17.5 million
Amount placed: $17.5 million
SEC filing: Source
First sale: 05-31-2017
Data as of: 06-12-2017